Gemifloxacin is approved to treat acute bacterial exacerbations of chronic bronchitis (AECB). Patients with AECB associated with COPD and a history of recurrent acute episodes can be difficult to treat. Data from 10 AECB clinical trials were analysed for number of exacerbations in last year (NELY), disease duration, history of asthma or chronic bronchitis.
Clinical response (success/failure) at end of therapy (EOT), follow-up Clinical response at end of therapy (EOT), follow-up and long follow-up (LFU, +2/52) was evaluated. Comparators were clarithromycin, levofloxacin, trovafloxacin, amoxycillin-clavulanate, ceftriaxone/cefuroxime and ofloxacin.
These data support the utility of gemifloxacin in AECB. Improved success at FU and LFU suggests that use of gemifloxacin may reduce time before next exacerbation with COPD patients.
Combined COPD/Respiratory medical histories show higher clinical success with gemifloxacin at FU and LFU.
I Morrissey, Grant monies (from industry related sources) Oscient; Shareholder Oscient; Employee Oscient; Consultant fee, speaker bureau, advisory committee, etc. Oscient.